Technical and clinical outcomes of microwave ablation for HCC: a single-center retrospective analysis of percutaneous ultrasound-guided, intraoperative ultrasound-guided and CT hepatic arteriography-guided approaches.
1/5 보강
[OBJECTIVES] To compare technical/clinical outcomes of microwave ablations (MWA) for hepatocellular carcinoma (HCC) performed with percutaneous ultrasound (US)-guidance, intraoperative ultrasound (IOU
- p-value p = 0.04
- p-value p = 0.003
APA
Muglia R, Laudicina P, et al. (2026). Technical and clinical outcomes of microwave ablation for HCC: a single-center retrospective analysis of percutaneous ultrasound-guided, intraoperative ultrasound-guided and CT hepatic arteriography-guided approaches.. La Radiologia medica. https://doi.org/10.1007/s11547-026-02207-y
MLA
Muglia R, et al.. "Technical and clinical outcomes of microwave ablation for HCC: a single-center retrospective analysis of percutaneous ultrasound-guided, intraoperative ultrasound-guided and CT hepatic arteriography-guided approaches.." La Radiologia medica, 2026.
PMID
41874943 ↗
Abstract 한글 요약
[OBJECTIVES] To compare technical/clinical outcomes of microwave ablations (MWA) for hepatocellular carcinoma (HCC) performed with percutaneous ultrasound (US)-guidance, intraoperative ultrasound (IOUS)-guidance or CT hepatic arteriography (CTHA)-guidance.
[MATERIALS & METHODS] This single-center retrospective study included 111 non-randomized patients (M:F = 91:20, median age 66y, range 51-86) with 200 HCCs (BCLC 0-A-B), treated with 136 MWA procedures (66 US-guided, 36 IOUS-guided, 34 CTHA-guided) between July 1, 2017, and January 31, 2025, with at least 6 months of clinical and CT/MRI follow-up. We evaluated patients' and nodules' characteristics, radicality (absent residual tumor at follow-up), local tumor progression, additional treatments, adverse events (CIRSE classification) and mortality. For patients undergoing multiple ablations, clinical outcomes were analyzed in relation to the first treatment.
[RESULTS] One nodule was ablated in 94/136 (69.1%) procedures, 2 nodules in 25/136 (18.4%), > 3 in 17/136 (12.5%). We encountered 13 adverse events, with the highest severity in IOUS-guided MWAs (1 grade 3, 2 grade 6). Fifty-eight patients (52.3%) progressed in other segments, subsequent treatments were performed in 57/111 (51.3%) patients and 28/111 (25.2%) died during follow-up. IOUS-guided MWA was associated with the highest radicality rate (56/60, 93.3%, p = 0.04) compared to CTHA-guided (45/51, 88.2%) and US-guided (72/89, 80.9%) ablations. Treating multiple nodules increased complication risk (p = 0.003), impacting on radicality (p = 0.032). No differences were found for overall survival (p = 0.07) or progression-free survival (p = 0.584) among the techniques.
[CONCLUSIONS] IOUS-guidance for HCC ablation provided a higher radicality rate compared to CTHA- and ultrasound-guidance techniques, but carried a higher risk of severe complications.
[MATERIALS & METHODS] This single-center retrospective study included 111 non-randomized patients (M:F = 91:20, median age 66y, range 51-86) with 200 HCCs (BCLC 0-A-B), treated with 136 MWA procedures (66 US-guided, 36 IOUS-guided, 34 CTHA-guided) between July 1, 2017, and January 31, 2025, with at least 6 months of clinical and CT/MRI follow-up. We evaluated patients' and nodules' characteristics, radicality (absent residual tumor at follow-up), local tumor progression, additional treatments, adverse events (CIRSE classification) and mortality. For patients undergoing multiple ablations, clinical outcomes were analyzed in relation to the first treatment.
[RESULTS] One nodule was ablated in 94/136 (69.1%) procedures, 2 nodules in 25/136 (18.4%), > 3 in 17/136 (12.5%). We encountered 13 adverse events, with the highest severity in IOUS-guided MWAs (1 grade 3, 2 grade 6). Fifty-eight patients (52.3%) progressed in other segments, subsequent treatments were performed in 57/111 (51.3%) patients and 28/111 (25.2%) died during follow-up. IOUS-guided MWA was associated with the highest radicality rate (56/60, 93.3%, p = 0.04) compared to CTHA-guided (45/51, 88.2%) and US-guided (72/89, 80.9%) ablations. Treating multiple nodules increased complication risk (p = 0.003), impacting on radicality (p = 0.032). No differences were found for overall survival (p = 0.07) or progression-free survival (p = 0.584) among the techniques.
[CONCLUSIONS] IOUS-guidance for HCC ablation provided a higher radicality rate compared to CTHA- and ultrasound-guidance techniques, but carried a higher risk of severe complications.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- CAR-T cells targeting activated hepatic stellate cells ameliorate liver fibrosis in mouse models.
- SIRT Combined with Targeted Therapy and Immunotherapy Achieves Sustained Complete Remission in Advanced Hepatocellular Carcinoma: A Case Report.
- The Novel HSF1 Inhibitor NXP800 Exhibits Robust Antitumor Activity in Hepatocellular Carcinoma.
- TATA-box binding protein-associated factor 2 (TAF2) in hepatocyte survival and tumorigenesis.
- B-mode and contrast-enhanced ultrasound versus magnetic resonance imaging in hepatic angiomyolipoma: a case report.
- Simultaneous Inhibition of MDM2 and XIAP by MX69 Induced Cell Cycle Arrest and Apoptosis in HUH7 and Hep3B Cell Lines.